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AbstrAct
background: The management of gastric adenocarcinoma is essentially based on surgery followed by adjuvant treatment. 
adjuvant chemotherapy (cT) as well as chemoradiotherapy (cTrT) have proven their effectiveness in survival outcomes 
compared to surgery alone. however, there is little data comparing the two adjuvant approaches. This study aimed to com-
pare the prognosis and survival outcomes of patients with gastric adenocarcinoma operated and treated by adjuvant radio-
chemotherapy or chemotherapy
Materials and methods: We retrospectively evaluated 80 patients with locally advanced gastric cancer (LGc) who received 
adjuvant treatment. We compared survival outcomes and patterns of recurrence of 53 patients treated by cTrT and those of 
27 patients treated by cT. 
results: after a median follow-up of 38.48 months, cTrT resulted in a significant improvement of the 5-year pFs (60.9% vs. 
36%, p = 0.03) and the 5-year Os (55.9% vs. 33%, p = 0.015) compared to adjuvant cT. The 5-year Os was significantly in-
creased by adjuvant cTrT (p = 0.046) in patients with lymph node metastasis, and particularly those with advanced pN stage  
(p = 0.0078) and high lymph node ratio (LNr) exceeding 25% (p = 0.012). also, there was a significant improvement of the pFs 
of patients classified pN2–N3 (p = 0.022) with a high LNr (p = 0.018). cTrT was also associated with improved Os and pFs in 
patients with lymphovascular and perineural invasion (LVI and pNI) compared to chemotherapy.
conclusion: There is a particular survival benefit of adding radiotherapy to chemotherapy in patients with selected criteria 
such as lymph node involvement, high LNr LVI, and pNI.
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Gastric cancer is the fifth most commonly di-
agnosed cancer in the world and the third lead-
ing cause of death related to cancer, representing 
a real health problem worldwide [1]. The overall 
survival rate of patients who have undergone only 
surgery is around 45% at 5 years and has undergone 
little change over the past decade. Local recurrences 
on the tumor bed, on the anastomosis, and in the 
locoregional lymph nodes occur in 40 to 65% of 
patients after resection for curative purposes. To 
compensate for this, an extension of the surgical 
procedure was recommended without reaching the 
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goal of improving survival or reducing the rate of 
locoregional recurrence [2, 3]. Thus, for patients 
with stage > IB, who are at high risk of recurrence, 
it is undoubtedly necessary that an adjuvant treat-
ment is offered after surgery [2, 4]. The gastro-
intestinal cancer intergroup (INT-0116) was the 
first phase III trial to demonstrate that adjuvant 
concomitant radio-chemotherapy improves recur-
rence-free survival and overall survival [5]. On the 
other hand, several meta-analyses have demonstrat-
ed the survival benefit of adjuvant chemotherapy in 
gastric cancer [6–8]. Furthermore, two randomized 
controlled phase III clinical trials showed that ad-
juvant therapy prolonged survival and decreased 
recurrence [5, 9]. Clinical trials have also directly 
compared postoperative CT alone with CRT for pa-
tients with locally advanced gastric cancer and the 
meta-analysis of three randomized clinical trials 
showed that CRT reduced the risk of locoregional 
relapses, but without significant improvement in 
distant relapse and overall survival [10]. Results 
of the ARTIST phase III randomized controlled 
trial showed that both adjuvant CT and CTRT are 
tolerated and equally beneficial in preventing re-
lapse and suggested that CTRT had significantly 
improved the DFS in patients with node-positive 
disease and with intestinal-type [11]. Given these 
results, the choice of the optimal adjuvant thera-
peutic attitude remains a subject of controversy. 
This study aimed to compare retrospectively the 
prognosis and survival outcomes of patients with 
gastric adenocarcinoma operated and treated by 
adjuvant radio-chemotherapy or chemotherapy 
alone and to assess the toxicity and safety of the tow 
treatment modalities to identify suitable patients 
for an intensified adjuvant treatment.
Materials and methods
patients
We retrospectively evaluated 80 patients with 
LGC who received adjuvant treatment from Janu-
ary 2005 to December 2015. Patients were eligible 
for analysis if they had histological confirmation of 
gastric cancer, had curative gastrectomy with nodal 
dissection. Exclusion criteria included the use of 
neoadjuvant treatment, metastatic disease at diag-
nosis, and patients with coexisting malignancies or 
those who could not tolerate the adjuvant treatment 
because of other systemic diseases.
We started identifying medical files, clinic (age, 
gender, reason of counseling, WHO status), endo-
scopic data (tumors site, size, aspect), tumor mark-
ers (CA 19-9 and CEA level), histological data (his-
tological type, tumors size, differentiation grade, 
number of removed nodes, parietal infiltration 
depth, lymphovascular invasion (LVI), perineu-
ral tumor invasion (PNI), lymph node status and 
the lymph node ratio (LNR) that corresponded to 
the ratio between metastatic and dissected lymph 
nodes. The lymph nodes metastasis (N stage) and 
the depth of invasion (T stage) were classified 
according to the TNM staging system  8th edi-
tion elaborated by the American Joint Commit-
tee on Cancer/International Union Against Cancer 
(AJCC/UICC) TNM staging system (AJCC/UICC). 
In this study, Histological classification was based 
on the WHO classification and Lauren classifica-
tion with 3 subgroups: intestinal type, diffuse type, 
and mixed type [12]. Poorly differentiated tumors 
included moderately differentiated tubular adeno-
carcinoma, independent signet ring cells adenocar-
cinoma, and mucinous adenocarcinoma.
surgical procedure
The surgical variables included the type of proce-
dure (total versus partial gastrectomy), the extent of 
lymph node dissection (D0, D1.5, and D2) based on 
the different updated versions of the Japanese Gastric 
Cancer Treatment Guidelines [13–15]. Lymphad-
enectomy was classified into three types according 
to the site of the tumor and the type of gastrecto-
my: D1 dissection, D1.5 dissection, and D2 dissec-
tion. A D1.5 lymphadenectomy corresponds to a D2 
lymphadenectomy with no dissection of the hilar and 
the splenic artery (relay 10 and 11).  Splenectomy was 
performed in cases of metastatic lymph nodes at the 
hilum of the spleen or because of iatrogenic injury. 
The extent of stomach resection was related to the 
primary tumor site: total gastrectomy was performed 
in all proximal tumor locations and total gastric tu-
mors, and subtotal gastrectomy was performed for 
distal tumor locations, provided that a 5- to 6-cm 
safety margin was present. After undergoing gas-
trectomy, patients were assigned to either adjuvant 
chemo radiotherapy or adjuvant chemotherapy.
adjuvant chemotherapy
We used 4 regimens of adjuvant chemothera-
py: The LV5FU2 regimen consisted of Leucovo-
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rin 100 mg/m2 in 2 hours infusion days 1–2 and 
5-FU 400 mg/m2 as a bolus followed by daily 22 
h infusion of 600 mg/m2 every 14 days for nine 
cycles. The ELF regimen consisted of Folinic acid 
at a dose of 300 mg/m2 given as a 10-minute IV 
infusion, followed immediately by Etoposide 120 
mg/m2 given as a 50-minute IV infusion, followed 
by bolus 5-FU 500 mg/m2 for 3 consecutive days. 
The cycles were repeated every 22 days. Patient 
treated with the FOLFOX4 regimen received an 
intravenous infusion of oxaliplatin (85 mg/m2 
2 hours) at day 1, a bolus injection of Leucovorin 
(200 mg/m2) at days 1–2, bolus injection of 5-FU 
(400 mg/m2) at days 1–2, and continuous intrave-
nous infusion of 5-FU (600 mg/m2) for 22 hours 
at days 1–2.
adjuvant chemo radiotherapy
In the CRT group, a contrast-enhanced com-
puted tomography scan with 3 mm-thick slices 
was conducted from the top of the diaphragm to 
the bottom of L4. The target volumes were defined 
as per INT 0116 protocol [16] and included the 
residual stomach, tumor bed, anastomosis, and the 
regional lymph nodes. Most radiotherapy plans 
were 3-dimensional conformal radiotherapy (3D-
CRT). Photon beams from linear accelerators with 
the energy of 6/10 or 6/23 MV were used for ra-
diotherapy planning. The planning target (PTV) 
volume for each patient was generated from the 
clinical target volume (CTV) plus 1 cm margins. 
The prescription dose was 45–50.4 Gy, with 1.8 Gy 
daily fractions administered over 5–5.6 weeks. As-
sociated chemotherapy regimen was based either 
on the INT 0116 trial using 5 cycles of intravenous 
bolus 5-fluorouracil and leucovorin (FUFOL regi-
men) before, during, and after radiotherapy, or 9 
cycles of simplified LV5FU2 regimen (two to four 
cycles before radiotherapy, then three cycles during 
radiotherapy and, finally, four cycles after radio-
therapy) delivered as follows: 2-hour infusion of 
leucovorin 200 mg/m2 on day 1 followed by a 400 
mg/m2 bolus of 5FU on day 1, then a continuous 
infusion of 5FU 2400 mg/m2 over 46 hours. Some 
patients received 6 cycles of modified FOLFOX 
(three cycles during radiotherapy and three cycles 
after radiotherapy) administrated as follows: ox-
aliplatin  85 mg/m2, leucovorin 200 mg/m2, bolus 
fluorouracil 400 mg/m2, and infusional fluoroura-
cil 1600 mg/m2).
Data regarding treatment toxicity were recorded 
according to the National Cancer Institute — Com-
mon Toxicity Criteria (NCI-CTC, version 4.0) (17).
statistical methods
The categorical variables were presented as num-
bers and percentages. Continuous variables were 
expressed as the mean ± standard deviation (SD) 
with ranges. Moreover, some continuous variables 
were converted to dichotomous variables for conve-
nience, including the age (< 70 years vs. ≥ 70 years), 
the weight loss (< 10% vs. ≥ 10%), the tumor size 
(< 50 mm vs. ≥ 50 mm) and the NRLN (≤ 15 LN 
vs. > 15 LN). To compare the continuous variables 
with normal distribution we used the T-test. To 
compare the categorical variables we used the c2 
or Fisher test if the assumption for the first has not 
complied.
OS was defined as the time from surgery to 
death, or the end of follow-up and PFS was de-
fined as the time from surgery to disease recur-
rence, as confirmed by using imaging. The rate and 
types of recurrence were compared between the 
two groups. Loco-regional recurrences correspond 
to recurrences occurring in the tumor bed, to anas-
tomotic and lymph node recurrences. Metastatic 
relapses corresponded to hepatic, peritoneal, bone, 
pulmonary, and ovarian sites. The Progression-free 
survival (DFS) and overall survival (OS) rates were 
obtained using the Kaplan Meier methods. In the 
case of comparing subgroups, the log-rank test was 
used. We used the Statistical Package for Social 
Science (SPSS), version 20.0 for Windows, and a p-
value less than 0.05 was considered significant.
results
patients’ characteristics
From January 2005 to December 2015, a total 
of 80 patients were eligible for the study, 53 in the 
CTRT group and 27 in the CT group. Baseline char-
acteristics are summarized in Table 1. Age, gender, 
performance status, and tumor location as well as 
surgical procedures were similar between groups. 
However, the proportion of patients with stage 
III/IV disease was significantly higher in the CT 
cohort than in the CTRT group (85.2% vs. 54.7%, 
p = 0.007). Groups were not balanced regarding 
the lymph node status: lymph node metastasis was 
more frequent in the CT group than in the CTRT 
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Men 48 (60%) 13(48.1%) 35 (66%)
0.122
Women 32 (40%) 14 (51.9%) 18 (34%)
age (years)
Mean ± sD [mm] 59.21± 12.89 62.66±11.43 57.45±13.33 0.087
≤ 65 55(68.8%) 17 (63%) 38 (71.7%)
0.425
> 65 25 (31.2%) 10 (37%) 15 (28.3%)
asa score
asa1–2 69 (86.2%) 24 (88.9%) 45 (84.9%)
0.625
asa3 11 (13.8%) 3 (11.1%) 8 (15.1%)
Weight loss
< 10% 31 (43.1%) 11(42.3%) 20 (45.5%)
0.923
≥ 10% 41 (56.9%) 15 (57.7%) 26 (56.5%)
Tumor location
proximal 10 (12.5%) 3 (11.1%) 7 (13.2%)
0.833Middle 1/3 29 (36.2%) 11 (40.7%) 18 (34%)
Distal 41 (51.2%) 13 (48.1%) 28 (52.8%)
UIcc stage
I–II 28 (35%) 4 (14.8%) 24 (45.3%)
0.007
III–IV 52 (65%) 23 (85.2%) 29 (54.7%)
UIcc stage
I 2 (2.5%) 0 (0%) 2 (3.8%)
0.014
II 26 (32.5%) 4(14.8%) 22 (41.5%)
III 47 (58.8%) 19(70.4%) 28 (52.8%)
IV 5 (6.2%) 4 (14.8%) 1 (1.9%)
pT stage
pT1 2(2.5%) 0 2(3,8%)
0.162
pT2 18(22.5%) 4(14,8%) 14(26,4%)
pT3 31(38.8%) 9 (33,3%) 22 (41,5%)
pT4 29 (36.2%) 14 (51,9%) 15(28,3%)
pN stage
N0 7 (8.8%) 0 7 (13.2%)
0.120
N1 20(25%) 8 (29.6%) 12 (22.6%)
N2 26 (32.5%) 7 (25.9%) 19 (35.8%)
N3 27 (33.8%) 12 (44.4%) 15 (28.3%)
LN status
N– 7 (8.8%) 0 7 (13.2%)
0.048
N+ 73 (91.2%) 27 (100%) 46 (86.8%)
LNr
≤ 25% 39 (48.8%) 12 (44.4%) 27 (50.9%)
0.582
> 25% 41 (51.2%) 15 (55.6%) 26 (49.1%)
NrLN
< 15 LN 16 (20%) 7 (25.9%) 9 (17%)
0.344
≥ 15 LN 64 (80%) 20 (74.1%) 44 (83%)
resection
TG 41 (51.2%) 13 (48.1%) 28 (52.8%)
0.692
pG 39 (48.8%) 14 (51.9%) 25 (47.2%)
LND
D1 7 (8.8%) 4 (14.8%) 3 (5.7%)
0.423D1.5 20 (25%) 6 (22.2%) 14 (26.4%)
D2 53 (66.2%) 17 (63%) 36 (67.9%)
Tumor size 
[mm]
< 50 mm 32 (40%) 12 (44.4%) 20 (37.7%)
0.592
≥ 50 mm 48 (60%) 15 (55.6%) 33 (62.3%)
Differentiation
Well   40 (50%) 11 (40.7%) 29 (54.7%)
0.358Moderly 23 (28.8%) 8 (29.6%) 15 (28.3%)
poorly 17 (21.2%) 8 (29.6%) 9 (17%)
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group (100% vs. 86.8%, p = 0.048) with more ad-
vanced N stage, (stage N3 accounted for 44.4% in 
the CT group vs. 28.3% in the CTRT group) and 
more patients with a LNR exceeding 25% (55.6% vs. 
49.1%). The two groups were comparable regarding 
the histological subtype, the grade of differentiation, 
and tumor size. However, lymphovascular space in-
vasion lymphovascular (LVI) were more frequent 
in the CT group than in the CRT group (59.3% vs. 
39.6%) and more perineural invasion (PNI) was ob-
served in the CT group (59.3 vs. 37.7%). However, 
these differences were not statistically significant 
(p = 0.096 and p = 0.067, respectively). 
adjuvant treatment 
Patients assigned to adjuvant chemotherapy re-
ceived variable regimens. From all, twelve patients 
received the LV5FU2 regimen (44.4%), 7 patients 
received the FOLFOX regimen (25.9%), 8 patients 
received the ELF regimen (29.6%), and two patients 
received ELF regimen (7.4%).
In the CTRT group, the most frequent associ-
ated chemotherapy was the LV5FU2 regimen in 41 
patients (77.4%), followed by the FUFOL regimen 
in 8 patients (15.1%) and the FOLFOX regimen in 
4 patients (7.5%).
Toxicity
The toxicity of each treatment is summarized in 
Table 2. The most frequent toxicity in the CTRT 
group were gastrointestinal in 37.7% of cases and 
hematologic toxicity in the CT group 66.66% of cas-
es. The most common grade 3 and 4 adverse events 
in the CT group were asthenia/anorexia (33.3%), 
hematologic (29.6%), and infectious (14.8%); while, 
the most common grade 3–4 adverse event in the 
CTRT was gastrointestinal toxicity (13.2%). No 
death during treatment was recorded in the two 
groups. Treatment discontinuity was recorded in 
26.4% of patients in the CTRT group (14 patients) 
and 29.6% in the CT group (8 patients). The most 
common cause of treatment discontinuity in the 
CTRT group was toxicity in 50% of cases followed 
by disease progression in 28.57% and loss of follow 
up in 21.42% of cases. For the CT group, treatment 
discontinuity was secondary to toxicity in 50% of 










Intestinal 59 (73.8%) 19 (70.4%) 40 (75.5%)
0.624
Mixed/diffuse 21 (26.2%) 8 (29.6%) 13(24.5%)
LVI
No 43 (53.8%) 11 (40.7%) 32 (60.4%)
0.096
Yes 37 (46.2%) 16 (59.3%) 31 (39.6%)
pNI
No 44 (55%) 11 (40.7%) 33 (62.3%)
0.067
Yes 36 (45%) 16 (59.3%) 20 (37.7%)
cT aDJ — adjuvant chemotherapy; cTrT — adjuvant radiochemotherapy; NrLN — number of retrieved lymph nodes; N– — no lymph node metastasis ,  
N+ — lymph node metastasis; LVI — lymphovascular invasion; pNI — perineural invasion
table 2. adverse events
Toxicity





















hematologic 4 (7.5%) 1 (1.88%) 3 (5.6%) 2 (3.7%) – 3 (11.1%) 7 (25.9%) 8 (29.6%) – –
Gastrointestinal 8 (15%) 5 (9.4%) 7 (13.2%) – – 2 (7.4%) 8 (29.2%) 2 (7.4%) 3 (11.1%) –
Mucositis 4 (7.5%) 2 (3.7%) 1 (1.88%) – – 5 (18.5%) 7 (25.9%) 4 (14.8%) 4 (14.8%) –
asthenia/ 
/anorexia
– 2 (3.7%) – – – 5 (18.5%) 6 (22.2%) 9 (33.3%) –
Neuropathy 1 (1.88%) 1 (1.88%) – – – 1 (3.7%) 3 (11.1%) 1 (3.7%) – –
Infectious – 1 (1.88%) – – – 1 (3.7%) 5 (18.5%) 4 (14.8%) – –
renal – – – – – – 4 (14.8%) – – –
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cases followed by disease progression in 37.5% and 
lost of follow up in 12.8% of cases. 
relapses and progression free survival
The median follow-up was 38.48 ± 28.67 months 
(range, 4–139 months). Data of the first relapse 
only were recorded and categorized as loco-re-
gional or distant (Tab. 3). After a mean follow-up 
of 18.85 ± 15.60 (3–75 months), recurrence oc-
curred in 42.5% of patients within 22.5 months in 
the CTRT group and 14 months in the CT group 
(p = 0.182). The overall rate of recurrence was 
higher in the CT group (55.6%) compared to the 
CTRT group (35.8%) without significant difference 
(p = 0.092). The frequency of locoregional and dis-
tant relapses was higher in the CT group (22.2% and 
44.4%, respectively) compared to the CTRT group 
(18.9% and 32.1%, respectively) without significant 
difference. Additionally, peritoneal recurrence was 
significantly higher in the CT group compared to 
the CTRT group (37% vs. 9.4%, p = 0.003). 
The 5-year PFS was 60.9% in the CTRT group 
and 36% in the CT group (p = 0.03) (Fig. 1). Sub-
group analyses were performed to identify patient 
populations who may benefit from CTRT (Tab. 4) 
showing that significant benefit from the addition 
of radiotherapy to adjuvant chemotherapy could 
not be excluded in women (p = 0.008), patients 
under 70 years old (p = 0.035), intestinal-type GC 
(p = 0.032), moderately/poorly differentiated tu-
mors (p = 0.022) and positive LVI tumor (p = 0.03) 
(Fig. 3). There also was a trend toward improved 
PFS with adjuvant CTRT in patients with ad-
vanced-stage III and IV (29.5% vs. 53.8%, p = 0.213) 
with increased outcomes especially in patients with 
pT3–T4 tumors (64% vs. 35.6%, p = 0.051). In the 
73 patients with node-positive disease, 5-year PFS 
was slightly different (59.9% in CTRT group vs. 
36% in CT group, p = 0.057) (Fig. 2). Furthermore, 
the subgroup analysis demonstrated the superior-
ity of adjuvant CTRT compared to CT in terms 
of PFS in patients classified pN2–N3 (57.8% vs. 
16.5%, p = 0.022) with a lymph node ratio greater 
than 25% (58.6% vs. 11.7%, p = 0.018). Moreover, 
we found that the benefit of adjuvant CTRT was 
statistically evident mainly for patients who had 
a D2 lymphadenectomy (56% vs. 28.4%, p = 0.01). 
Nevertheless, it seems that in patients who did not 
have extended lymphadenectomy, the CTRT brings 
a gain of 19.5% on PFS at 5 years but also an obvi-
ous increase in PFS in patients whose number of 









Overall recurrence 34 (42.5%) 15 (55.6%) 19 (35.8%) 0.092
Locoregional recurrence 16 (20%) 6 (22.2%) 10 (18.9%) 0.723
Distant recurrence 29 (36.3%) 12 (44.4%) 17 (32.1%) 0.277
peritoneal 15 (18.8%) 10 (37%) 5 (9.4%) 0.003
Liver 13 (16.3%) 6 (22.2%) 7 (13.2%) 0.301
Lung 8 (10%) 1 (3.7%) 7 (13.2%) 0.255
Ovary 2 (2.5%) 1 (3.7%) 1 (1.9%) 1
Bone 1 (1.3%) 0% 1 (1.9%) 1
*patients relapsed at multiple sites. The total number of recurrence sites was greater than the number of relapsed patients; cT — chemotherapy;  
cTrT — radio chemotherapy
Figure 1. Kaplan-Meier survival curves of progression-free 
survival in all patients. There was a significant difference 
between adjuvant chemotherapy (cT) group and adjuvant 
radiochemotherapy (cTrT) (p = 0.03)
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removed lymph nodes was less than 15 (77.8% vs. 
21.4%, p = 0.056).
Overall survival
The 5-year overall survival was significantly 
higher in the CTRT group compared to the CT 
group (55.9% vs. 33%, p = 0.015) (Fig. 5, Tab. 5). 
The subgroup analysis revealed that adjuvant CTRT 
resulted in an improved overall survival compared 
with adjuvant CT, especially in women (p = 0.014), 
patients with ASA score under 3 (p = 0.007), stage 
pT3–pT4 tumors (58.5% vs. 34.4%, p = 0.048), pa-





all patients (n = 80) 36% 60.9% 0.03
Gender
Men 51.4% 59.3% 0.671
Women 23.8% 64.8% 0.008
age (years)
< 70 32.1% 59.8% 0.035
≥ 70 47.6% 65.5% 0.440
asa score
asa1–2 36.1% 66.1% 0.014
asa3 33.3% 33.3% 0.918
Weight Loss
< 10% 56.1% 72.2% 0.613
≥ 10% 24.4% 51.9% 0.054
UIcc stage
I–II 75% 70.7% 0.801
III–IV 29.5% 53.8% 0.213
 pT stage
pT1–T2 37.5% 57.4% 0.416
pT3–T4 35.6% 64% 0,051
pN stage
N0–N1 72.8% 16.5% 0.919
N2–N3 16.5% 57.8% 0.022
LN status
N– – 66.7% Na
N+ 36% 59.9% 0.057
LNr
≤ 25% 61.4% 64.1% 0.708
> 25% 11.7% 58.6% 0.018
NrLN
< 15 LN 21.4% 77.8% 0.056
≥ 15 LN 41.3% 56.9% 0.182
resection
TG 38.1% 70.2% 0.077
pG 35.4% 50.9% 0.226
LND
D1/D1.5 50.6% 70.1% 0.581
D2 28.4% 56.3% 0.01
Tumor size [mm]
< 50 mm 37.4% 84.4% 0.016
≥ 50 mm 33.3% 45.1% 0.324
Differentiation
Well differentiated  78.8% 83% 0.661
Others 0% 30.1% 0.022
Lauren type
Intestinal 37.8% 68.8% 0.032
Mixed/diffuse 30% 33.8% 0.568
LVI
No 88.9% 86.7% 0.828
Yes 0% 20.6% 0.03
pNI
No 88.9% 90.1% 0.930
Yes 0% 13.5% 0.076
cT aDJ — adjuvant chemotherapy; cTrT — adjuvant radiochemotherapy; NrLN — number of retrieved lymph nodes; N– — no lymph node metastasis;  
N+ — lymph node metastasis; LVI — lymphovascular invasion; pNI — perineural invasion
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tients with lymph node metastasis (51.5% vs. 33%, 
p = 0.046) (Fig. 6) and particularly those with ad-
vanced pN stage (p = 0.0078) and high lymph node 
ratio exceeding 25% (49% vs. 8.8%, p = 0.012). 
Moreover, some histological criteria were associ-
ated with an improved overall survival with CTRT 
compared to adjuvant CT notably intestinal sub-
type (p = 0.017), LVI positive tumors (p = 0.006) 
(Fig. 7), PNI positive tumors (p = 0.027) (Fig. 8). 
In the case of D2 lymphadenectomy, the benefit in 
terms of overall survival was higher in the adjuvant 
CTRT group compared to the adjuvant CT group 
(51.5% vs. 29.4%, p = 0.008) on the other hand, 
there was no significant difference between the two 
groups in the event of D1–D1.5 lymphadenectomy 
with a gain of 20.9% in terms of OS at 5 years in 
the CTRT group. Also, the adjuvant CTRT allowed 
a 47.7% increase in the overall survival of patients 
whose number of lymph nodes removed was less 
than 15 compared to the adjuvant CT (p = 0.07).
Discussion
Despite the advancement in adjuvant and neoad-
juvant therapy, the 5-year survival rate for patients 
with positive lymph node gastric cancer is as low 
Figure 2. Kaplan-Meier survival curves of progression-free 
survival in lymph node-positive patients. There was a tendency 
to significant difference between adjuvant chemotherapy 
(cT) group and adjuvant radiochemotherapy (cTrT)  
(p = 0.057)
Figure 3. Kaplan-Meier survival curves of progression-free 
survival in LVI-positive patients. There was a significant 
difference between adjuvant chemotherapy (cT) group 
and adjuvant radiochemotherapy (cTrT) (p = 0.03)
Figure 4. Kaplan-Meier survival curves of progression-free 
survival in pNI-positive patients. There was a significant 
difference between adjuvant chemotherapy (cT) group 
and adjuvant radiochemotherapy (cTrT) (p = 0.076)
Figure 5. Kaplan-Meier survival curves of overall survival 
in all patients. There was a significant difference between 
adjuvant chemotherapy (cT) group and adjuvant 
radiochemotherapy (cTrT) (p = 0.015)
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as 15–20%, and even node-negative patients have 
a 5-year survival rate of 45–55% in the case of ad-
vanced T stage (T3–T4N0) [18] with recurrence 
rates ranging from 20% to 40% within 2 years after 
complete resections depending on specific factors 
such as the initial stage of the disease, proximal 
location and Lauren’s histological type [19]. These 
data justify the need for an adapted or even inten-
sified adjuvant therapeutic strategy to reduce the 
relapse rate depending on these prognostic factors. 
Although the role of adjuvant chemotherapy (CT) 
has been established and adjuvant CT is routinely 





all patient (n = 80) 33% 55.9% 0.015
Gender
Men 43.1% 54.7% 0.300
Women 23.6% 58.9% 0.014
age (years)
< 70 31% 59.2% 0.033
≥ 70 37.5% 40.4% 0.304
asa score
asa1–2 32.9% 60.7% 0.007
asa3 33.3% 25% 0.976
Weight Loss
< 10% 42.4% 64.4% 0.230
≥ 10% 29.6% 43.9% 0.131
UIcc stage
I–II 50% 70.9% 0.176
III–IV 29.3% 42.8% 0.260
 pT stage
pT1–T2 25% 51.4% 0.112
pT3–T4 34.4% 58.5% 0.048
pN stage
N0–N1 75% 69.1% 0.948
N2–N3 13% 48.8% 0.007
LN status
N– - 83.3% Na
N+ 33% 51.5% 0.046
LNr
≤ 25% 57.1% 62.7% 0.437
> 25% 8.8% 49% 0.012
NrLN
< 15 LN 19% 66.7% 0.07
≥ 15 LN 36.6% 53.1% 0.08
resection
TG 28% 64.5% 0.016
pG 39% 47.4% 0.277
LND
D1/D1.5 42.2% 63.1% 0.472
D2 29.4% 51.5% 0.008
Tumor size [mm]
< 50 mm 33.3% 84.7% 0.002
≥ 50 mm 33.3% 36.9% 0.471
Differentiation
Well differentiated  79.5% 77.2% 0.858
Others 0% 29% 0.007
Lauren type
Intestinal 33.8% 62.2% 0.017
Mixed/diffuse 30% 32.6% 0.483
LVI
No 90 % 76.9% 0.507
Yes 0% 23.7% 0.006
pNI
No 90% 8.3% 0.659
Yes 0% 16.3% 0.027
cT aDJ — adjuvant chemotherapy; cTrT — adjuvant radiochemotherapy; NrLN — number of retrieved lymph nodes; N–  — no lymph node metastasis;  
N+ — lymph node metastasis; LVI — lymphovascular invasion; pNI— perineural invasion
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used for D2-dissected gastric cancer, the value of 
combining postoperative RT with CT is still largely 
debated. Our study suggested the superiority of 
adjuvant CTRT to adjuvant CT not only in terms 
of reducing the risk of overall recurrence but also 
in improving the 5-year OS, especially in patients 
with lymph node metastasis, high LNR and lym-
phovascular and perineural invasion which is the 
most interesting feature. Moreover, based on the 
literature data, we aimed to identify selection cri-
teria to propose intensive adjuvant treatment for 
a subgroup of patients presenting conventional pe-
jorative prognostic factors of survival. These results 
were consistent with data from the literature regard-
ing the prognostic impact of CTRT on recurrence. 
However, it seems that our study is distinguished by 
encouraging results in favor of CTRT in improving 
overall survival (55.9% vs. 33%; p = 0.015). 
Very few studies have compared adjuvant CT 
with adjuvant CTRT and most of them did not 
show a significant improvement of overall sur-
vival by associating RT to CT despite the gain in 
terms of recurrence survival. The ARTIST trial was 
the first phase III study that compared the adju-
vant treatment with chemotherapy (6 cycles of XP 
— capecitabine and cisplatin) in 172 patients vs. the 
association of chemotherapy and radiotherapy (2 
cycles of XP + XP and radiotherapy + 2 more cycles 
of XP) in 188 patients after D2-lymphadenectomy 
[20]. The addition of XRT to XP chemotherapy 
did not significantly prolong the 3-year disease-free 
survival (DFS) (78.2% vs. 74.2%; p = 0.862). More-
over, in the updating of their results after 7 years 
of follow-up, DFS remained similar between treat-
ment arms (HR = 0.740; 95% CI = 0.520–1.050; 
p = 0.0922), OS was also similar (HR = 1.130; 95% 
CI = 0.775–1.647; p = 0.5272) but the addition 
of radiotherapy provided an improvement in dis-
ease-free survival for node-positive patients [11]. 
In a South Korean phase III study of Kim et al,  90 
patients having had R0 surgery with D2 dissection 
were randomized between two arms: an adjuvant 
CT arm (44 patients) and an adjuvant CTRT arm 
(46 patients) [21]. In this study, although five-year 
Figure 8. Kaplan-Meier survival curves of overall survival 
in patient with pNI positive tumors. There was a significant 
difference between adjuvant chemotherapy (cT) group 
and adjuvant radiochemotherapy (cTrT) (p = 0.027)
 
Figure 6. Kaplan-Meier survival curves of overall survival 
in lymp node-positive patients. There was a significant 
difference between adjuvant chemotherapy (cT) group 
and adjuvant radiochemotherapy (cTrT) (p = 0.046)
Figure 7. Kaplan-Meier survival curves of overall survival 
in patient with LVI positive tumors. There was a significant 
difference between adjuvant chemotherapy (cT) group 
and adjuvant radiochemotherapy (cTrT) (p = 0.006)
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disease-free survival (DFS), which was the pri-
mary endpoint of this trial, was not significantly 
improved in the combined modality, locoregional 
recurrence-free survival (LRRFS) (93.2% vs. 66.8%, 
p = 0.014) and metastatic recurrence-free survival 
(73.5% vs. 54.6%, p = 0.056) were improved. In 
contrast to these two trials, a significant benefit in 
5-year RFS (45.2% vs. 35.8; p = 0.012), but not in 
OS, was shown in a Chinese multicenter random-
ized trial in which patients with D2-dissection were 
randomly assigned to chemotherapy alone (165 
patients) or intensity-modulated RT plus concur-
rent chemotherapy (IMRT-C) (186 patients) [22]. 
In this study, the IMRT-C was associated with an 
increase in the median duration of RFS compared 
to chemotherapy (50 months vs. 32 months) and 
the hazard ratio for recurrence was 1.35 (95% CI: 
1.03–1.78; p = 0.029). These data support our re-
sults as we found significant improvement in PFS 
at 5 years (60.9% vs. 36%, p = 0.03) with adjuvant 
radiochemotherapy compared to adjuvant CT. 
The analysis of the patterns of recurrence of 
our patients revealed that locoregional and dis-
tant relapses were more frequent in the adjuvant 
CT group than in the CTRT group without a sig-
nificant statistical difference, which is in line with 
the results of the ARTIST trial where locoregional 
relapse was more frequent in the XP arm (13%) 
than in the XPRT arm (7%; p = 0.033) and dis-
tant metastases were observed in 27% and 24% of 
patients in the XP and XPRT arms, respectively 
(p = 0.5568) [11]. Moreover, in the randomized 
study of Zhu et al. the rate of distant metastasis was 
slightly higher in the chemotherapy group (26.7% 
vs. 24.2%, p = 0.595) [22]. 
The meta analysis of the results of the two ran-
domized controlled trials from South Korea [20, 
21] and the study of China [22] comparing ad-
juvant chemotherapy and CRT, which included 
a total of 895 patients, showed that postoperative 
CTRT significantly improved locoregional recur-
rence-free survival (HR = 0.53, 95% CI = 0.32–0.87, 
p = 0.01) and disease-free survival (HR = 0.72, 95% 
CI = 0.59–0.89, p = 0.002); without a significant 
improvement of distant metastasis recurrence-free 
survival (HR = 0.86; 95% CI = 0.66–1.11; p = 0.25) 
and overall survival (HR = 0.79, 95% CI = 0.61–1.03, 
p = 0.08) [10]. 
In our study, the analysis of subgroups according 
to the extent of lymphadenectomy had demonstrat-
ed the superiority of CTRT to CT as an adjuvant 
treatment to D2 lymphadenectomy both in terms 
of OS and PFS. In the group of patients with less 
extensive lymphadenectomy, CTRT offered a bet-
ter OS (19% vs. 66.7%) and PFS (21.4% vs. 77.8%) 
without significant difference. This last observation 
agrees with the data from the SWOG/INT-0116 
trial where the CTRT improved the oncological 
results of all patients who had mostly had D0–D1 
dissection [23]. Paradoxically, Dikken et al. had 
retrospectively compared survival and recurrence 
patterns of 91 patients in phase I and II studies 
evaluating more intensified postoperative CRT with 
694 patients from the Dutch Gastric Cancer Group 
Trial (DGCT) that randomly assigned patients be-
tween D1 and D2 lymphadenectomy and suggested 
that the addition of CTRT seemed to be beneficial 
in preventing local recurrence after D1-dissection, 
but not after D2-dissection [24].
Consequently, the role of adjuvant RT remains 
unclear after an adequate lymphadenectomy but 
it seems that the identification of a high-risk sub-
group for loco-regional recurrence among D2-dis-
sected patients is essential and of higher priority 
than assessing the efficacy of a regular application 
of adjuvant CRT in all D2-dissected gastric cancer 
patients [25]. 
Regardless of the type of lymphadenectomy, the 
lymph node status remains largely involved in the 
therapeutic indications since it represents a prog-
nostic factor determining survival and recurrence 
[26, 27]. In fact, in our study, the adjuvant CTRT 
allowed a significant improvement in the overall 
5-year survival of patients with lymph node in-
volvement (p = 0.046), with a tendency to better 
progression-free survival (p = 0.057). These data 
appear to be consistent with those of the ARTIST 
trial where the subgroup analysis of 396 patients 
with node-positive disease revealed that the 3-year 
DFS was significantly improved in the XPRT arm 
compared to the XP arm (76% vs. 72% in XPRT 
arm; p = 0.04) and found that in patients without 
lymph node involvement, chemotherapy would 
be more beneficial than CTRT in terms of DFS 
(HR = 1.359, 95% CI = 0.477–3.876) with no sig-
nificant difference [11]. Moreover, we have found 
that the benefit provided by the adjuvant CTRT in 
terms of OS (13% vs. 48.8%, p = 0.0078), but espe-
cially in terms of PFS (16.5% vs. 57.8%, p = 0.022), 
was significantly higher than the adjuvant CT, es-
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pecially in patients with more advanced pN stages 
(pN2–pN3). This is consistent with the Korean re-
port of Chang et al. which revealed that N3 patients 
are at substantial risk of regional recurrence as well 
as peritoneal and distant spread despite D2 dissec-
tion and adjuvant chemotherapy suggesting that an 
intensified treatment by chemoradiotherapy would 
improve survival outcomes [28].
As lymph node ratio (LNR) was previously iden-
tified as an independent prognostic factor after D1 
and D2 lymph node dissections [29, 30], we com-
pared the prognostic impact of adjuvant CTRT to 
that of adjuvant CT according to the lymph node 
ratio. This subgroup analysis had demonstrated 
that, unlike patients whose LNR was less than 25%, 
those whose lymph node ratio was greater than 
25% and treated with adjuvant CTRT had a sig-
nificant gain of 40.2% in terms of OS at 5 years 
and 46.9% in terms of PFS at 5 years compared 
to patients who received adjuvant CT. These find-
ings are consistent with the results of the subgroup 
analysis of the ARTIST trial were the effect of ra-
diotherapy in patients with a high lymph node ratio 
(≥ 0.083) was different from the effect in patients 
with a low lymph node ratio in both DFS (HR = 2.03; 
95% CI = 1.44–2.87; p < 0.01) and overall survival 
(HR = 1.98; 95% CI = 1.38–2.83; p < 0.01) suggest-
ing that the lymph node ratio might represent an 
absolute, reproducible factor that could help se-
lect patients for CTRT [11]. On the other hand, 
the integration of the notion of the lymph node 
ratio during the evaluation of the prognostic con-
tribution of adjuvant CTRT was mentioned in the 
retrospective study by Costa et al. [31]. Indeed, 
this study included 142 patients (90 patients treat-
ed with surgery only and 52 patients treated with 
resection followed by adjuvant CTRT) classified 
according to the LNR (NR0 = 0%, NR1 = 1–9%, 
NR2 = 10–25%, NR3 > 25%) and concluded that 
the individuals with a lower LNR had no benefit 
with adjuvant CTRT both in OS (78.8% vs. 76.9%) 
and DFS (81.8% vs. 76.9%), whereas those with 
a higher LNR treated by CTRT had a significant 
improvement in OS (71.4% vs. 30.9%; p = 0.038) 
and superior but not statistically significant gain 
regarding DFS (48.9% vs. 30.3%; p = 0.145). In view 
of these data, it seems that lymph node involvement 
represents a decisive element in favor of the inten-
sification of the adjuvant treatment of locally ad-
vanced gastric cancers by associating radiotherapy 
with chemotherapy, which represents the rationale 
of the ongoing ARTIST II trial aiming to evaluate 
the benefit of adjuvant combined therapy only in 
pN+ patients.
Depth of parietal invasion has long been con-
sidered an independent factor for survival and 
recurrence in gastric cancer [32–34] and authors 
consider this parameter as a determining factor of 
the delay of relapses. In fact, in the study by Otsuji 
[35], the depth of parietal infiltration represents an 
independent factor determining the time to recur-
rence with a median time of 11.7 months in the 
T4 stages, and 15.5 months in the pT3 stages, 22.2 
months in pT2 stages, and 39.5 months in pT1 
stages without forgetting that lymph node involve-
ment is significantly correlated with the depth of 
parietal invasion. Based on these data, we suggest 
a combined strategy for T3–T4 tumors as we found 
that in this group of patients the benefit provided 
by CTRT compared to CT both in terms of OS 
(34.4% vs. 58.5%; p = 0.048) and PFS (35.6% vs. 
64%; p = 0.051) is superior. Whereas in the case of 
earlier tumors the two strategies remain compa-
rable. 
Moreover, as PNI and LVI have been investigated 
as prognostic factors of recurrence and overall sur-
vival in resected gastric cancer [36, 37], we found 
that CTRT provided better overall survival rates 
and lower recurrence in the subgroup of patients 
with PNI and LVI compared to adjuvant chemo-
therapy and this significant difference was not re-
ported in cases of PNI and LVI negative tumors. 
Our findings are similar to those reported by Yu et 
al. who evaluated the influence of adjuvant RT on 
recurrence at each locoregional subsite, and inves-
tigated which subgroups received the most benefit 
by comparing failure patterns between CCRT and 
chemotherapy groups of the ARTIST trial [38]. In 
this study, the authors used Forest plots to repre-
sent locoregional recurrence-free survival (LRRFS) 
HRs and 95% CIs and demonstrated that patients 
with lymphovascular invasion (HR = 0.45, 95% 
CI = 0.22–0.90, p = 0.02) showed greater LRRFS 
benefit from XPRT than XP. It is therefore wise to 
consider that these two histological data would be 
helpful to select patients for an intensified treat-
ment with radiotherapy as suggested by the review 
of Agolli et al. [39]. 
In addition, the results of our study agree with 
those of the Mac Donald trial suggesting that post-
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operative CTRT would be more effective in the 
intestinal type [16]. The ARTIST trial also dem-
onstrated that the effect of the addition of radio-
therapy on DFS and OS differed by Lauren clas-
sification (interaction p = 0.04 for PFS; interaction 
p = 0.03 for OS). The Forest plot of HRs and 95% 
CIs for disease-free survival revealed that the ef-
fect of radiotherapy in patients with intestinal-type 
GC (HR = 0.442, 95% CI = 0.231–0.845) was dif-
ferent from the effect in patients with diffuse GC 
(HR = 0.826, 95% CI = 0.543–1.255) [11]. 
And, finally, in 2016, in the CRITICS study, 788 
patients were randomized after preoperative che-
motherapy with ECX or EOX and surgery between 
a group of postoperative chemotherapy (393 pa-
tients) and a group of postoperative radiochemo-
therapy (395 patients) [40]. This international study 
showed the absence of difference in terms of OS be-
tween the two groups (41.3% in the CT adj arm and 
40.9% in the CTRT adj arm, p = 0.99) with different 
profiles of toxicity: higher grade III hematological 
toxicity in the adj CT arm (44% vs. 34%; p = 0.01) 
and higher grade III gastrointestinal toxicity in the 
CTRT arm (37% vs. 42%; p = 0.14), which is in 
line with our results where the rate of grade 3–4 
gastrointestinal toxicity was 22.6% in the CTRT 
group and 18.5% in the CT group and the rate of 
grade 3–4 hematological toxicity was higher in the 
CT group (29.6%) than in the CTRT group (9.3%). 
Moreover, most comparative studies have shown 
no increase in grade 3–4 treatment-related toxicity 
in the CTRT group with modern RT techniques 
(IMRT or CT-based 3D-CRT) compared with the 
chemotherapy alone group [10]. 
However, our study has certain limitations. In-
deed, this is a retrospective monocentric study in-
cluding a small number of patients with variable 
CT regimens, which leads to a higher risk of selec-
tion bias. Furthermore, there was a different stage 
distribution between the two groups, with more 
stage III patients in the CT group than in the CRT 
group (70.4% vs. 52.8%; p = 0.014), which reflects 
the attitude adopted in our institution favoring an 
aggressive systemic treatment strategy for locally 
advanced tumors likely to present a higher risk 
of metastatic recurrence rather than locoregional 
recurrence. This high rate of stage III in the CT 
group did not translate into a statistically signifi-
cant difference in terms of survival and CTRT was 
still superior to adjuvant CT. In addition, our study 
included patients whose lymphadenectomy was not 
extensive with a rate of D1-lymphadenectomy of 
8.8% and a number of LN lower than 15 in 20% of 
the cases. However, our results remain interpretable 
since the interest of an extended lymphadenectomy 
remains a subject of controversy in the area of ad-
juvant therapies and new techniques of irradiation 
taking into account the morbidity associated with 
lymph node surgery reported in the majority of 
randomized studies.
conclusion
Even if there are no strict recommendations con-
cerning the intensification of the adjuvant treatment 
of locally advanced gastric cancers by associating 
radiotherapy with chemotherapy, the indication of 
this combined approach should take into account 
the prognostic factors that have a significant im-
pact on recurrence and survival outcomes to select 
patients who can benefit from this approach, es-
pecially those with lymph node involvement, high 
LNR LVI, and PNI. 
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